On 23 January 2019, the European Data Protection Board (EDPB)
adopted an Opinion on the interplay between the Clinical
Trials Regulation (CTR), which is likely to become applicable in
2020 (if not later), and the European General Data Protection
Regulation (GDPR). The Opinion focusses on an area provoking much
discussion since the GDPR came into force; that is, as we discussed
in our previous blog, which legal bases under the GDPR are
appropriate for processing personal data in the context of clinical
trials?
The Consent Overlap
While focussing on the CTR, the principles in the Opinion would
apply equally to the Clinical Trials Directive. In all cases, the
sponsor must obtain the explicit, unambiguous and freely given
consent of subjects before commencing the trial. This consent
requirement is distinct from any consent provided under the GDPR as
a legal basis for processing personal data.